Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
As the ATMP industry matures and therapeutics see more and more regulatory success, the gene editing and particularly CRISPR development market has been growing in the background. The first CRISPR therapeutics are entering the clinic, and the recent boom in activity in expected to continue.
In this workshop, designed as an introductory course for industry professionals less familiar with CRISPR, we will cover
Change is inevitable and necessary both in development and over the post-approval product lifecycle. Whenever changes are made it is necessary to confirm they do not adversely impact the quality and therefore safety and efficacy of the product; this requires data beyond meeting current specifications. With any biological product this is challenging, for cell, gene and tissue products that cannot be fully characterised the challenges are greater still. Concerns about comparability undertaken during development are common issues raised during review and often delay market approval or contribute to failure. This course explains what comparability is and how to develop a successful comparability protocol.
Workshop Learning Overview
• What is comparability?
• Why is meeting existing specifications not comparability?
• How do I apply the principles of comparability to highly variable products?
• Case studies: Common mistakes with comparability and their consequences.
• Interactive exercise: Spot the weaknesses and propose improvements to a worked comparability study.